2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6244 Overcoming barriers to trial enrollment utilizing an intentional decentralized approach focused on enhanced access

Geoffrey Shouse, DO PhD, Lu Chen, PhD2, Chijioke C Nze, MD, MPH3, Tanya Siddiqi, MD4, Brian Sworder, MD, PhD5, Alexandra Muir, BSN, RN6, Azra Borogovac, MD7, Rahul Polineni, MD8, Christina Poh, MD9, Idoroenyi Amanam, MD10, Alexey V. Danilov, MD, PhD11, Alex Francisco Herrera, MD12
1 City of Hope Comprehensive Cancer Center, Duarte, California, United States
2 City of Hope Comprehensive Cancer Center, Duarte, California, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 City of Hope Comprehensive Cancer Center, Duarte, California, United States
5 City of Hope Comprehensive Cancer Center, Duarte, California, United States
6 City of Hope Comprehensive Cancer Center, Duarte, California, United States
7 City of Hope Comprehensive Cancer Center, Duarte, California, United States
8 City of Hope Comprehensive Cancer Center, Duarte, California, United States
9 City of Hope Comprehensive Cancer Center, Duarte, California, United States
10 City of Hope Comprehensive Cancer Center, Duarte, California, United States
11 City of Hope Comprehensive Cancer Center, Duarte, California, United States
12 City of Hope Comprehensive Cancer Center, Duarte, California, United States

Background. The treatment landscape for B-cell non-Hodgkin lymphoma (B-NHL) has seen a dramatic shift toward molecular targeted, immune, and other novel therapies driven largely by clinical trials demonstrating safety and efficacy. Significant barriers exist to trial enrollment at multiple levels leading to clinical trial populations that are not representative of population demographics. These disparities persist despite better understanding and attempts at improvement. Here we report data from a decentralized prospective interventional study in B-NHL intentionally designed to reduce barriers to enrollment and enhance access to cutting edge clinical trial therapy across a broadly representative patient population.

Methods.  This ongoing, open-label, investigator-sponsored trial is enrolling adult (age≥18) patients (pts) with B-NHL into either cohort1 (self-reported ethnic/racial minority; planned enrollment 25) or cohort2 (non-Hispanic White[NHW]/Asian; planned enrollment 10). B-NHL subtypes include treatment naïve or relapsed/refractory [r/r] CLL, MCL, MZL r/r to ≥1 prior therapy, and non-GCB DLBCL r/r to ≥2 prior therapies. Pts are treated with zanubrutinib (zanu) and sonrotoclax (sonro) on 28-day cycles with a 2-cycle zanu lead-in followed by a 1-cycle sonro ramp-up. Tele health visits and decentralized lab testing were utilized including outpt TLS monitoring during sonro ramp to ease travel/logistical burdens on pts. The co-primary endpoints are feasibility of (1) completing 75% of planned doses of zanu/sonro during cycle 1-3, completing sonro ramp-up in ≤5 weeks and completing 75% of TLS monitoring, and (2) completing 75% of planned doses for cycle 4-5. Secondary objectives include safety, response, survival and a survey assessing patient factors, barriers to opportunity, and attitudes and perspectives about clinical trial enrollment.

Results. Eighteen pts have enrolled, with 17 starting treatment including 10 in cohort1 (5 Hispanic[H], 5 Black[B]) and 7 in cohort2 (6 NHW, 1 Asian). The median age is 67 (range 29-86) years, 13 pts had CLL, 2 had DLBCL, and 2 had MCL. For primary endpoint 1, 3 are pending evaluation; of 14 evaluable pts, 7 met the endpoint requirements (50%), 4 did not complete 3 cycles of treatment due to relapse/progression (n=2), medication noncompliance (n=1), and death from disease progression (n=1), while 3 additional pts completed C1-3 with incomplete pill diary documentation. For primary endpoint 2, among 9 patients who started cycle 4, 3 are pending evaluation; of the 6 evaluable pts, all 6 completed cycle 4-5, but 2 had incomplete pill diaries (67%). No unexpected safety signals were seen, including no TLS and no pts stopped treatment due to toxicity.

Survey data taken at baseline evaluating barriers to trial enrollment were available for 13 treated pts including 8 pts from cohort1 (4H and 4B) and 5 pts from cohort2 (NHW). Patients in cohort1 faced long distance travel to cancer doctor’s office (25% 1-2 hours and 25% 2-5 hours vs 80% <1 hour in C2). Cohort1 patients also demonstrated metrics of poor overall health (50% taking >5 medications, 62.5% rating their health as fair or poor, and 75% reporting functional compromise). In addition, only 25% of cohort1 patients reported trial treatment as very safe, only 25% reported trial treatment was associated with better care while 87.5% of cohort1 pts reported concern about how much the trial would cost them. Trust in treating physician was reported at 100% across both cohorts, while 25% of cohort pts believed they received medication from a physician as part of an experiment without their permission at some time vs 0% in cohort2.

Conclusions.  Here we describe enrollment of a clinical trial population representative of population demographics by utilizing an intentional approach to overcome barriers to trial enrollment. However, the interim feasibility analysis has not met the 75% threshold (50% for endpoint 1 and 67% for endpoint 2). Alternatives to pill diaries such as electronic medication monitoring will be explored to enhance capture of true medication adherence. Baseline survey data demonstrate important barriers to trial enrollment faced by traditionally underrepresented minority groups including travel burden, skepticism about safety and concerns about cost which may help inform future strategies to improve trial representation.

Geoffrey Shouse, DO PhD: Kite Pharma - Honoraria; ADC Therapeutics - Honoraria; BeOne Medicines - Honoraria; AstraZeneca - Honoraria; BMS - Consultancy (Includes expert testimony); Marker Therapeutics - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony)